The 5-year relative survival rate for children with brain and other CNS tumors in the United States reaches 75%. Median age at diagnosis for pediatric medulloblastoma stands at 6 years, while the rate falls to about 22% for children with glioblastoma. This article compiles incidence figures, treatment outcomes, diagnostic approaches, and trial trends across these tumor types.
Key Takeaways
- The 5-year relative survival rate for children with brain and other CNS tumors in the United States is 75%
- The median age at diagnosis of pediatric medulloblastoma is 6 years
- About 20% of pediatric ependymomas arise in the fourth ventricle
- The global pediatric oncology therapeutics market was forecast to grow at a CAGR of 11.5% from 2024 to 2032
- The global medulloblastoma therapeutics market is forecast to grow at a CAGR of 12.2% from 2024 to 2032
- The global glioma therapeutics market is forecast to grow at a CAGR of 10.7% from 2024 to 2032
- The 5-year relative survival for children with glioblastoma is about 22%
- High-dose chemotherapy with autologous stem cell rescue is used in about 20% of recurrent pediatric medulloblastoma cases
- In a phase 2 trial of vismodegib for adults with basal cell-related tumors, hedgehog pathway inhibition showed an objective response rate of 19% (benchmark for pathway-targeted therapy relevance to SHH-driven tumors)
- MRI is the primary diagnostic imaging modality for pediatric brain tumors
- Neurofibromatosis type 2 (NF2) is associated with meningioma and ependymoma syndromes; germline NF2 mutations account for a subset of ependymoma cases
- A review reports that 18F-FET PET can change management in suspected recurrent glioma cases in a clinically meaningful fraction of patients
- Academic and nonprofit consortia increasingly combine genomic profiling with clinical trial matching (basket/umbrella designs) for pediatric brain tumor patients
- Molecularly targeted therapies are being trialed across multiple pediatric brain tumor subgroups; targeted trials represent a growing share of pediatric neuro-oncology studies in registries
- The International Cancer Genome Consortium (ICGC) established a Pediatric Cancer program in 2016 with the goal to sequence 2,000 pediatric cancer genomes
Pediatric brain tumor survival is improving, with MRI-led diagnosis and targeted therapies driving better outcomes.
Related reading
01 · Category
Incidence & Demographics3 stats
01
The 5-year relative survival rate for children with brain and other CNS tumors in the United States is 75%
02
The median age at diagnosis of pediatric medulloblastoma is 6 years
03
About 20% of pediatric ependymomas arise in the fourth ventricle
Interpretation
Incidence & Demographics Interpretation
Within pediatric brain tumor incidence and demographics, the median age for medulloblastoma is 6 years while roughly 20% of ependymomas originate in the fourth ventricle, and despite these age and tumor-location patterns the 5 year relative survival rate in the United States is 75%.
02 · Category
Market Size5 stats
01
The global pediatric oncology therapeutics market was forecast to grow at a CAGR of 11.5% from 2024 to 2032
02
The global medulloblastoma therapeutics market is forecast to grow at a CAGR of 12.2% from 2024 to 2032
03
The global glioma therapeutics market is forecast to grow at a CAGR of 10.7% from 2024 to 2032
04
The CAR-T therapy market is forecast to reach US$40.2 billion by 2032
05
The radiation therapy equipment market is forecast to reach US$14.7 billion by 2032
Interpretation
Market Size Interpretation
The pediatric brain tumor market is set for strong growth, with pediatric oncology therapeutics projected to expand at an 11.5% CAGR from 2024 to 2032 and related segments like medulloblastoma therapeutics rising at a 12.2% CAGR, signaling expanding investment in treatment options across this market category.
03 · Category
Treatment & Outcomes7 stats
01
The 5-year relative survival for children with glioblastoma is about 22%
02
High-dose chemotherapy with autologous stem cell rescue is used in about 20% of recurrent pediatric medulloblastoma cases
03
In a phase 2 trial of vismodegib for adults with basal cell-related tumors, hedgehog pathway inhibition showed an objective response rate of 19% (benchmark for pathway-targeted therapy relevance to SHH-driven tumors)
04
In the randomized trial of systemic therapy for children with high-risk medulloblastoma, 3-year progression-free survival was 59% (standard vs investigational comparisons reported in the trial)
05
In the randomized phase 3 trial for newly diagnosed pediatric high-risk medulloblastoma, overall survival at 5 years was 77% for the standard arm
06
In the St. Jude Total Therapy study for pediatric medulloblastoma, 5-year event-free survival exceeded 75% (risk-adapted protocols)
07
Leptomeningeal dissemination occurs in approximately 30%–40% of children at diagnosis for certain embryonal tumors involving CNS spread
Interpretation
Treatment & Outcomes Interpretation
For Pediatric Brain Tumor treatment and outcomes, the best signals come from medulloblastoma where modern risk adapted and randomized strategies reach 5-year overall survival around 77% and 5-year event free survival above 75%, even as glioblastoma outcomes remain far lower with only about 22% 5-year relative survival.
More related reading
04 · Category
Diagnostics & Biomarkers2 stats
01
MRI is the primary diagnostic imaging modality for pediatric brain tumors
02
Neurofibromatosis type 2 (NF2) is associated with meningioma and ependymoma syndromes; germline NF2 mutations account for a subset of ependymoma cases
Interpretation
Diagnostics & Biomarkers Interpretation
MRI is the primary diagnostic imaging tool for pediatric brain tumors, and when paired with biomarker-oriented genetics like germline NF2 mutations linked to ependymoma syndromes, it suggests diagnostics increasingly combine imaging-first detection with targeted molecular risk context.
05 · Category
Industry Trends5 stats
01
A review reports that 18F-FET PET can change management in suspected recurrent glioma cases in a clinically meaningful fraction of patients
02
Academic and nonprofit consortia increasingly combine genomic profiling with clinical trial matching (basket/umbrella designs) for pediatric brain tumor patients
03
Molecularly targeted therapies are being trialed across multiple pediatric brain tumor subgroups; targeted trials represent a growing share of pediatric neuro-oncology studies in registries
04
Real-world adoption of hypofractionated radiotherapy schedules is growing in pediatric settings where clinically appropriate, supported by evolving clinical evidence
05
AI-assisted segmentation and treatment planning tools are increasingly evaluated for radiotherapy workflows; published studies report improved contouring consistency compared with manual methods
Interpretation
Industry Trends Interpretation
Industry trends in pediatric brain tumor care are shifting rapidly as multiple innovations move from research into practice, including 18F-FET PET changing management in a clinically meaningful fraction of suspected recurrent glioma patients and a growing use of genomic profiling with trial matching and AI-assisted radiotherapy planning tools.
06 · Category
Regulatory & Policy3 stats
01
The International Cancer Genome Consortium (ICGC) established a Pediatric Cancer program in 2016 with the goal to sequence 2,000 pediatric cancer genomes
02
The Cancer Moonshot initiative set a target to reduce cancer death rates by at least 50% by 2047 (policy-level public health target)
03
The US FDA Modernization Act 2.0 (2022) included provisions affecting pediatric oncology development through expanded data standards and review modernization
Interpretation
Regulatory & Policy Interpretation
Regulatory and policy efforts are increasingly pushing pediatric brain tumor research forward through concrete targets and standards, from the ICGC’s 2016 goal to sequence 2,000 pediatric cancers to the Cancer Moonshot’s aim to cut cancer deaths by at least 50 percent by 2047 and the FDA Modernization Act 2.0’s 2022 updates expanding data requirements for pediatric oncology.
report visual · Comparison
Survival varies widely by pediatric brain tumor type
5-year relative survival rates differ substantially between broader brain/CNS tumors and glioblastoma.
The 5-year relative survival rate for children with brain and other CNS tumors in the United States is 75%75%
The 5-year relative survival for children with glioblastoma is about 22%
22%
The median age at diagnosis of pediatric medulloblastoma is 6 years
6
source-verifiedseer.cancer.gov · acsjournals.onlinelibrary.wiley.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Pediatric Brain Tumor Statistics. Gitnux. https://gitnux.org/pediatric-brain-tumor-statistics
MLA
Marcus Afolabi. "Pediatric Brain Tumor Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pediatric-brain-tumor-statistics.
Chicago
Marcus Afolabi. 2026. "Pediatric Brain Tumor Statistics." Gitnux. https://gitnux.org/pediatric-brain-tumor-statistics.
Sources & references
25 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)